AIMS: While natriuretic peptides have demonstrated diagnostic and prognostic potential in cardiac disorders, little is known about their relationship with the onset and quantification of myocardial infarction. The relationship of serial N-terminal pro-brain natriuretic peptide (NT-proBNP) with duration from symptom onset, infarct size and prognosis in ST elevation myocardial infarction (STEMI) patients treated with primary percutaneous intervention was examined. METHODS AND RESULTS: Three hundred thirty-one STEMI patients in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial, which evaluated pexelizumab versus placebo, were studied. NT-proBNP (pg/mL) was measured at randomization, 24 h and 72 h; creatine kinase-MB area under the curve was measured at 72 h; and QRS score was assessed at discharge. Prognosis was ascertained from the 90-day composite clinical outcome of death, shock, stroke and congestive heart failure. Multivariate logistical regression was used to adjust for baseline characteristics for models at randomization, 24 h and 72 h. NT-proBNP was higher in patients with longer time from symptom onset (P<0.001) and correlated with measures of infarct size, including the area under the curve (P<0.001) and QRS score (P<0.001). Patients reaching the primary end point had markedly higher NT-proBNP at each sampling period (P<0.001). NT-proBNP at all time points was the strongest independent predictor of the primary end point in the multivariate model: in the 24 h model, only age and 24 h NT-proBNP (C-index 0.83); and only age, Killip class and NT-proBNP was in the 72 h model (C-index 0.85). CONCLUSIONS: Higher NT-proBNP at 24 h correlated with larger infarct size and worse clinical outcomes. NT-proBNP at baseline, 24 h and 72 h after presentation with acute STEMI, is an independent predictor of a poor outcome and adds clinically useful prognostic information.
AIMS: While natriuretic peptides have demonstrated diagnostic and prognostic potential in cardiac disorders, little is known about their relationship with the onset and quantification of myocardial infarction. The relationship of serial N-terminal pro-brain natriuretic peptide (NT-proBNP) with duration from symptom onset, infarct size and prognosis in ST elevation myocardial infarction (STEMI) patients treated with primary percutaneous intervention was examined. METHODS AND RESULTS: Three hundred thirty-one STEMI patients in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial, which evaluated pexelizumab versus placebo, were studied. NT-proBNP (pg/mL) was measured at randomization, 24 h and 72 h; creatine kinase-MB area under the curve was measured at 72 h; and QRS score was assessed at discharge. Prognosis was ascertained from the 90-day composite clinical outcome of death, shock, stroke and congestive heart failure. Multivariate logistical regression was used to adjust for baseline characteristics for models at randomization, 24 h and 72 h. NT-proBNP was higher in patients with longer time from symptom onset (P<0.001) and correlated with measures of infarct size, including the area under the curve (P<0.001) and QRS score (P<0.001). Patients reaching the primary end point had markedly higher NT-proBNP at each sampling period (P<0.001). NT-proBNP at all time points was the strongest independent predictor of the primary end point in the multivariate model: in the 24 h model, only age and 24 h NT-proBNP (C-index 0.83); and only age, Killip class and NT-proBNP was in the 72 h model (C-index 0.85). CONCLUSIONS: Higher NT-proBNP at 24 h correlated with larger infarct size and worse clinical outcomes. NT-proBNP at baseline, 24 h and 72 h after presentation with acute STEMI, is an independent predictor of a poor outcome and adds clinically useful prognostic information.
Authors: A M Richards; M G Nicholls; T G Yandle; C Frampton; E A Espiner; J G Turner; R C Buttimore; J G Lainchbury; J M Elliott; H Ikram; I G Crozier; D W Smyth Journal: Circulation Date: 1998-05-19 Impact factor: 29.690
Authors: S Talwar; I B Squire; P F Downie; A M Mccullough; M C Campton; J E Davies; D B Barnett; L L Ng Journal: Eur Heart J Date: 2000-09 Impact factor: 29.983
Authors: T Omland; A Aakvaag; V V Bonarjee; K Caidahl; R T Lie; D W Nilsen; J A Sundsfjord; K Dickstein Journal: Circulation Date: 1996-06-01 Impact factor: 29.690
Authors: N B Hindman; D D Schocken; M Widmann; W D Anderson; R D White; S Leggett; R E Ideker; T Hinohara; R H Selvester; G S Wagner Journal: Am J Cardiol Date: 1985-06-01 Impact factor: 2.778
Authors: N Hama; H Itoh; G Shirakami; O Nakagawa; S Suga; Y Ogawa; I Masuda; K Nakanishi; T Yoshimasa; Y Hashimoto Journal: Circulation Date: 1995-09-15 Impact factor: 29.690
Authors: Sean van Diepen; Wendimagegn G Alemayehu; Yinggan Zheng; Pierre Theroux; L Kristin Newby; Kenneth W Mahaffey; Christopher B Granger; Paul W Armstrong Journal: J Thromb Thrombolysis Date: 2016-10 Impact factor: 2.300
Authors: Dirk Aam Schellings; Ahmet Adiyaman; Jan-Henk E Dambrink; At Marcel Gosselink; Elvin Kedhi; Vincent Roolvink; Jan Paul Ottervanger; Arnoud Wj Van't Hof Journal: Vasc Health Risk Manag Date: 2016-11-21
Authors: D A A M Schellings; A W J van 't Hof; J M Ten Berg; A Elvan; E Giannitsis; C Hamm; H Suryapranata; A Adiyaman Journal: Neth Heart J Date: 2017-04 Impact factor: 2.380
Authors: M Hromádka; V Černá; M Pešta; A Kučerová; J Jarkovský; D Rajdl; R Rokyta; Z Moťovská Journal: Dis Markers Date: 2019-11-03 Impact factor: 3.434